ISA Pharmaceuticals closes a License Agreement with Transgene aimed at the development of novel vaccines for TB

May 26, 2011

Leiden, The Netherlands, May 26th, 2011 – ISA Pharmaceuticals B.V., a private, clinical stage company and leader in the development of immunotherapeutic products for oncology and infectious diseases, and Transgene (Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced the signing of an exclusive license agreement. Transgene will use ISA’s proprietary IP in Transgene’s program for developing novel vaccines to combat infectious diseases caused by mycobateria tuberculosis, such as TB. Under the terms of the agreement, ISA will receive an upfront fee and could receive payments on the achievement by Transgene of research and clinical milestones, as well as royalties on the sales of products resulting from the agreement. Financial details of the agreement were not disclosed. “We are very pleased to collaborate with Transgene, since we strongly believe that ISA’s IP combined with Transgene’s expertise in vaccine development will yield breakthrough products”, said Gerard Platenburg, CEO of ISA. About Transgene Transgene, a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases and has five compounds in clinical development: TG4010 and JX-594/TG6006 having completed initial Phase II trials, TG4001 in Phase IIb trial, TG4040 in Phase II trial and TG4023 in Phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products: an option agreement with Novartis for the development of TG4010 to treat various cancers; and, an in-licensing agreement with US-based Jennerex Biotherapeutics, Inc., to develop and market JX-594/TG6006, an oncolytic product. Transgene also has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available at www.transgene.fr. About ISA ISA Pharmaceuticals is dedicated to fighting cancer and infectious diseases by providing novel immunotherapeutics based on its proprietary SLP® technology to activate and employ the patient's own immune system. Its most advanced product is a highly efficacious therapeutic product against HPV-induced lesions. The company was founded in 2004 by Aglaia Oncology Fund and has its roots in the ground-breaking research performed by the group of the internationally renowned tumor immunologist Professor Kees Melief. R&D is performed in close collaboration with the Leiden University Medical Center, the Netherlands. www.isa-pharma.com. ISA Pharmaceuticals B.V. Gerard Platenburg CEO Tel: + 31 (0) 6 53439090 E-mail: platenburg@isa-pharma.com